Fluoxetine + Dextroamphetamine Saccharate Amphetamine Aspartate Monohydra Interaction
Majorinteraction on record
Description
CYP2D6 inhibitor and serotonergic drug that increases amphetamine exposure and risk of serotonin syndrome. Initiate with lower doses and monitor for serotonin syndrome.
Mechanism
CYP2D6 inhibition increases amphetamine exposure; serotonergic interaction increases serotonin syndrome risk
Source: NLP:dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate